Back to Resources
Market Highlights
- During Q3 2025, companies in the diabetes glucagon market maintained an active presence across monitored social media platforms and corporate websites. Three of the five operated branded websites, with Novo Nordisk being the only one to manage an unbranded page.
- Lupin expanded its U.S. injectable portfolio with FDA approval of Glucagon and continued its #HealWithLupin awareness campaign.
- Novo Nordisk emphasized community engagement through its partnership with the University of Oxford on the Cities for Better Health initiative.
- Xeris promoted the Gvoke HypoPen as a ready-to-use option and supported hypoglycemia awareness by sponsoring the “Let’s Talk Lows” initiative with Beyond Type 1.
Questions about this SnapShot or other markets?
U.S. MARKETS
Christine Alongi
alongi@dtwresearch.com
GLOBAL MARKETS
Robin Cefalo
cefalo@dtwresearch.com
SOCIAL MEDIA MARKETS
Andrew Carney
carney@dtwresearch.com